{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"40.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"description":"Percentage of participants with Dose Limiting Toxicities (DLTs), based on investigator assessment, for determination of Maximum Tolerated Dose (MTD). MTD was defined as the dose in which less than 2 of up to 6 patients developed a DLT.","groups":[{"description":"Patients received oral administration of afatinib 90mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle.","id":"OG000","title":"Afatinib 90mg"},{"description":"Patients received oral administration of afatinib 120mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle.","id":"OG001","title":"Afatinib 120mg"},{"description":"Patients received oral administration of afatinib 150mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle.","id":"OG002","title":"Afatinib 150mg"},{"description":"Patients received oral administration of afatinib 160mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle.","id":"OG003","title":"Afatinib 160mg"},{"description":"Patients received oral administration of afatinib 200mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle.","id":"OG004","title":"Afatinib 200mg"}],"paramType":"NUMBER","populationDescription":"Treated set including patients eligible for MTD determination","reportingStatus":"POSTED","timeFrame":"28 days","title":"Percentage of Participants With Dose Limiting Toxicities","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}